Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Peffault de Latour R, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, Zhang L, Griffin M, Langemeijer SMC, Panse J, Schrezenmeier H, Barcellini W, Mauad VAQ, Schafhausen P, Tavitian S, Beggiato E, Chew LP, Gaya A, Huang WH, Jang JH, Kitawaki T, Kutlar A, Notaro R, Pullarkat V, Schubert J, Terriou L, Uchiyama M, Wong Lee Lee L, Yap ES, Sicre de Fontbrune F, Marano L, Alashkar F, Gandhi S, Trikha R, Yang C, Liu H, Kelly RJ, Höchsmann B, Kerloeguen C, Banerjee P, Levitch R, Kumar R, Wang Z, Thorburn C, Maitra S, Li S, Verles A, Dahlke M, Risitano AM. Peffault de Latour R, et al. Among authors: pullarkat v. N Engl J Med. 2024 Mar 14;390(11):994-1008. doi: 10.1056/NEJMoa2308695. N Engl J Med. 2024. PMID: 38477987
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Zeidan AM, et al. Among authors: pullarkat v. Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5. Lancet Haematol. 2024. PMID: 38065203 Clinical Trial.
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
Tinajero J, Ngo D, Zhang J, Tsai NC, Aribi A, Aldoss I, Agrawal V, Arslan S, Amanam I, Pourhassan H, Sandhu K, Al-Malki M, Pullarkat V, Becker P, Nakamura R, Stein A, Marcucci G, Artz A, Koller P, Salhotra A. Tinajero J, et al. Among authors: pullarkat v. Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38635368 No abstract available.
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Othman T, Koller P, Pourhassan H, Agrawal V, Ngo D, Tinajero J, Ali H, Cai JL, Mei M, Aribi A, Stein AS, Marcucci G, Forman SJ, Pullarkat V, Aldoss I. Othman T, et al. Among authors: pullarkat v. Br J Haematol. 2024 May 29. doi: 10.1111/bjh.19551. Online ahead of print. Br J Haematol. 2024. PMID: 38808512 No abstract available.
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Othman T, Koller P, Tsai NC, Yang D, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Spielberger R, Sahebi F, Al Malki MM, Cai JL, Sandhu KS, Mansour J, Salhotra A, Ali H, Aribi A, Arslan S, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Aldoss I, Mei M. Othman T, et al. Among authors: pullarkat v. Am J Hematol. 2024 May 28. doi: 10.1002/ajh.27378. Online ahead of print. Am J Hematol. 2024. PMID: 38804599
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Othman T, Li S, Zhang J, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Sahebi F, Sandhu K, Spielberger R, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Mei M, Aldoss I, Koller P. Othman T, et al. Among authors: pullarkat v. Am J Hematol. 2024 May 27. doi: 10.1002/ajh.27365. Online ahead of print. Am J Hematol. 2024. PMID: 38800943
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg A, Stein E, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Bewersdorf JP, et al. Among authors: pullarkat v. Am J Hematol. 2024 May 15. doi: 10.1002/ajh.27366. Online ahead of print. Am J Hematol. 2024. PMID: 38751104 No abstract available.
Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
Pourhassan H, Zhang J, Tinajero J, Pullarkat V, Agrawal V, Koller P, Al Malki M, Aribi A, Salhotra A, Sandhu K, Ali H, Stein A, Marcucci G, Forman S, Aldoss I. Pourhassan H, et al. Among authors: pullarkat v. Br J Haematol. 2024 Mar 31. doi: 10.1111/bjh.19432. Online ahead of print. Br J Haematol. 2024. PMID: 38556836
203 results